Downstaging of hepatocellular carcinoma and liver metastases from colorectal cancer by selective intra-arterial chemotherapy - PubMed (original) (raw)
Downstaging of hepatocellular carcinoma and liver metastases from colorectal cancer by selective intra-arterial chemotherapy
Pierre-Alain Clavien et al. Surgery. 2002 Apr.
Abstract
Background: Although resection is the sole chance of cure in patients with hepatocellular carcinoma (HCC) or metastatic colorectal cancer to the liver, most patients are not candidates for surgery at the time of diagnosis. Strategies aiming at downstaging large or multifocal tumors to enable curative resection are appealing. The aim of this study was to evaluate the effects of neoadjuvant selective intra-arterial chemotherapy in noncirrhotic patients with unresectable HCC or metastatic colorectal cancer to the liver in the absence of extrahepatic disease.
Methods: Selective chemotherapy was provided by using a subcutaneous pump device via a catheter placed in the gastroduodenal artery. Chemotherapy regimen included floxuridine (0.2 mg/kg/day for 14 days) in each patient with additional boluses of cisplatin and doxorubicin on day 1 of each cycle in the presence of HCC. Patients were evaluated at 3, 6, 9, and 12 months for possible curative resection. Complete follow-up was available for each patient.
Results: Twenty-eight patients with unresectable liver tumors (5 HCC and 23 metastatic colorectal cancer) were included in this study. There were no surgical complications related to pump insertion, and local chemotherapy was started within 1 week of surgery in each patient. The median follow-up in survivors was 31 months (range, 30 months to 5 years). Chemotherapy was well tolerated in 18 (64%) patients. Chemotherapy was discontinued in 4 patients because of abnormal liver function test results, and 2 of them required a biliary stent to relieve a biliary stricture. In 9 patients downstaging enabled curative resection (3 HCC, 6 colorectal metastasis). Seven of these patients were alive and tumor free at the completion of the study, with at least 2 years of follow-up. The actuarial survival rates at 3 years for HCC and colorectal metastases were 60% and 50%, respectively.
Conclusions: About one third of patients with unresectable liver tumors can be successfully treated by neoadjuvant intra-arterial chemotherapy followed by curative resection. This strategy appears particularly promising in patients with large HCC. This approach should be investigated further.
Similar articles
- Surgery after downstaging of unresectable hepatic tumors with intra-arterial chemotherapy.
Meric F, Patt YZ, Curley SA, Chase J, Roh MS, Vauthey JN, Ellis LM. Meric F, et al. Ann Surg Oncol. 2000 Aug;7(7):490-5. doi: 10.1007/s10434-000-0490-2. Ann Surg Oncol. 2000. PMID: 10947016 - A pilot study of hepatic artery floxuridine combined with systemic 5-fluorouracil and leucovorin. A potential adjuvant program after resection of colorectal hepatic metastases.
Kemeny N, Conti JA, Sigurdson E, Cohen A, Seiter K, Lincer R, Niedzwiecki D, Botet J, Chapman D, Costa P, et al. Kemeny N, et al. Cancer. 1993 Mar 15;71(6):1964-71. doi: 10.1002/1097-0142(19930315)71:6<1964::aid-cncr2820710607>3.0.co;2-t. Cancer. 1993. PMID: 8443746 Clinical Trial. - Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer.
Kemeny N, Huang Y, Cohen AM, Shi W, Conti JA, Brennan MF, Bertino JR, Turnbull AD, Sullivan D, Stockman J, Blumgart LH, Fong Y. Kemeny N, et al. N Engl J Med. 1999 Dec 30;341(27):2039-48. doi: 10.1056/NEJM199912303412702. N Engl J Med. 1999. PMID: 10615075 Clinical Trial. - [Adjuvant intra-arterial chemotherapy after curative resection of liver metastasis from colorectal cancer. Results of a pilot study in 30 patients].
Gambiez L, Denimal F, Karoui M, Dewailly V, Pruvot FR, Quandalle P. Gambiez L, et al. Chirurgie. 1999 Dec;124(6):640-8. doi: 10.1016/s0001-4001(99)00073-2. Chirurgie. 1999. PMID: 10676025 Review. French. - Place of hepatic intra-arterial chemotherapy in the treatment of colorectal liver metastases.
Allard MA, Malka D. Allard MA, et al. J Visc Surg. 2014 Apr;151 Suppl 1:S21-4. doi: 10.1016/j.jviscsurg.2013.12.003. Epub 2014 Mar 11. J Visc Surg. 2014. PMID: 24636278 Review.
Cited by
- Effects of hepatic arterial infusion chemotherapy in the treatment of hepatocellular carcinoma: A meta-analysis.
Long GB, Xiao CW, Zhao XY, Zhang J, Li X. Long GB, et al. Medicine (Baltimore). 2020 Jun 26;99(26):e20745. doi: 10.1097/MD.0000000000020745. Medicine (Baltimore). 2020. PMID: 32590750 Free PMC article. - Transplant Oncology: An Emerging Discipline of Cancer Treatment.
Abdelrahim M, Esmail A, Abudayyeh A, Murakami N, Victor D, Kodali S, Cheah YL, Simon CJ, Noureddin M, Connor A, Saharia A, Moore LW, Heyne K, Kaseb AO, Gaber AO, Ghobrial RM. Abdelrahim M, et al. Cancers (Basel). 2023 Nov 9;15(22):5337. doi: 10.3390/cancers15225337. Cancers (Basel). 2023. PMID: 38001597 Free PMC article. Review. - Management of hepatocellular carcinoma.
Cormier JN, Thomas KT, Chari RS, Pinson CW. Cormier JN, et al. J Gastrointest Surg. 2006 May;10(5):761-80. doi: 10.1016/j.gassur.2005.10.006. J Gastrointest Surg. 2006. PMID: 16713550 Review. - Living donor liver transplantation for unresectable colorectal liver metastasis: Report of a case with 13-year follow-up without recurrence.
Choi JU, Hwang S, Jung DH, Park GC, Ahn CS, Kim KH, Moon DB, Ha TY, Song GW, Lee SG. Choi JU, et al. Ann Hepatobiliary Pancreat Surg. 2020 May 31;24(2):188-191. doi: 10.14701/ahbps.2020.24.2.188. Ann Hepatobiliary Pancreat Surg. 2020. PMID: 32457265 Free PMC article. - Efficacy of hepatic arterial infusion chemotherapy in advanced hepatocellular carcinoma.
Baek YH, Kim KT, Lee SW, Jeong JS, Park BH, Nam KJ, Cho JH, Kim YH, Roh YH, Lee HS, Choi YM, Han SY. Baek YH, et al. World J Gastroenterol. 2012 Jul 14;18(26):3426-34. doi: 10.3748/wjg.v18.i26.3426. World J Gastroenterol. 2012. PMID: 22807613 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical